Yarbrough Capital’s Astrana Health ASTH Stock Holding History

Yarbrough Capital’s Portfolio ASTH Stock Details ASTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,894	Closed	-$394K	–	156
2025 Q4	$394K	Buy	+15,894	New	+$422K	0.01%	127

Other funds holding ASTH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Yarbrough Capital's ASTH Position: Q1 2026 in Review

Yarbrough Capital sold out of Astrana Health (ASTH) in Q1 2026, closing a stake of 15,894 shares — an estimated $394K sold.

Yarbrough Capital first reported a position in ASTH in Q4 2025 and held it in 1 quarter. The position peaked at $394K in Q4 2025. 171 funds tracked by Wall St. Rank hold ASTH as of Q1 2026.

Yarbrough Capital reported no remaining Astrana Health position as of Q1 2026 after selling out during the quarter.
Yarbrough Capital sold 15,894 Astrana Health shares in Q1 2026, an estimated $394K.
Yarbrough Capital first reported a position in Astrana Health in Q4 2025 and held it in 1 quarter.
Yarbrough Capital's Astrana Health position peaked at $394K in Q4 2025.
171 funds tracked by Wall St. Rank held Astrana Health as of Q1 2026.

Based on Yarbrough Capital's 13F filing for Q1 2026, filed 14 Apr 2026.